Editor’s note: The omicron variant of SARS-CoV-2, the virus that causes COVID-19, has fueled a rapid surge in cases globally. We asked a team of virologists and immunologists from the University of Colorado Boulder to weigh in on some of the pressing questions that people are asking about the new variant.
How is omicron different from previous variants?
There are two key differences between omicron and previous variants of the SARS-CoV-2 virus that emerged in late 2019. Early data suggests that omicron cases are milder than infections caused by the delta variant. On the flip side, omicron is far more transmissible – meaning it spreads easier – than previous variants. It can be confusing to think about the overall effects of a milder virus that is also far more infectious.
When the delta variant became dominant and displaced alpha in the summer of 2021, it managed to do so because it was between 40% and 60% more transmissible. Now, the omicron variant is even more transmissible than delta.
It’s difficult to put numbers around how intrinsically more transmissible one variant is than another, because human behaviors and vaccination percentages are constantly in flux. Those factors, together with transmissibility, affect how a virus fares in a population.
In comparison with the original strain of SARS-CoV-2, omicron contains 72 mutations throughout its genome. Some of these mutations account for the complex new features that characterize this variant. Half of those changes are in the spike protein, the critical surface protein that enables the virus to latch on and infect cells. It is also the key virus feature that is recognized by the human immune system.
Why is omicron spreading so quickly?
Initial studies suggest that omicron is more effective at reproducing in the upper airways, including the nose, throat and mouth, than earlier variants, making it more similar to a common cold virus. If data from these preliminary studies holds up, then it may help explain omicron’s high transmissibility: Viruses replicating in the upper airways may spread more easily, although the reasons for this are not completely understood.
In addition, omicron is often able to evade existing immunity long enough to start an infection, cause symptoms and transmit onward to the next person. This explains why reinfections and vaccine breakthrough infections seem to be more common with omicron.
Those properties, and the timing of this variant emerging during the holiday season, resulted in the extraordinary surge in COVID-19 infections in the U.S. Add in wintertime – which brought people indoors – along with pandemic fatigue, and you have the perfect storm for rapid transmission.
The good news is that vaccination and vaccine boosters nevertheless provide good protection against severe disease and hospitalization. But given the current number of cases, that still means a lot of illnesses, hospitalizations and deaths in the weeks to come.
Could omicron move the population closer to herd immunity?
Herd immunity occurs when enough people have immunity to a virus that it no longer spreads well. It is only possible when two conditions are met. First, a large fraction of the population must be vaccinated or recovered from prior infection. Second, vaccination or prior infection must confer enough immunity to block or slow future infections. Will vaccination campaigns, combined with widespread omicron infection, be enough to bring herd immunity?
Three issues complicate the hope of achieving a long-term herd immunity after omicron. The first is that immunity naturally wanes over time, regardless of whether it comes from a vaccine or prior infection. It is not yet clear how long after infection or vaccination immunity to this virus lasts, since SARS-CoV-2 has been infecting humans for only two years. Eventually, controlled studies will be able to determine this.
Second, children younger than age 5 are not yet eligible for COVID-19 vaccines, and new susceptible children are born every day. So, until all age groups are eligible for vaccination, there will likely be ongoing transmission in kids.
And third, we can’t rule out that new variants could escape existing immunity. As omicron has shown, infection with one variant doesn’t guarantee protection against infection by future variants.
Together, these three factors suggest that even if a large enough fraction of the population recovers from omicron, long-term herd immunity is unlikely. These are the same reasons that humans never achieve long-lasting herd immunity to influenza and have to get a new flu vaccine each year.
It’s important to remember that, with all variants to date, most of the people who are hospitalized for COVID-19 are unvaccinated. This shows that vaccines are an effective tool for reducing disease severity and can be beneficial even against new variants.
Where do new variants like omicron come from?
When viruses make more copies of themselves inside of human cells, they make mistakes in that process – mutations – that alter their genetic code. Most of these mutations will not be beneficial to the virus. However, in some instances, a virus hits on a jackpot of one or more beneficial mutations that fuel its spread through a population. The alpha variant possessed some mutations in the spike protein that made it easier for viruses to infect cells. The delta variant had additional mutations that improved viral spread. Omicron, with its staggering number of mutations, is a true oddity. It’s rare for a coronavirus to rapidly accumulate so many mutations in its genome.
The origins of omicron are still poorly understood. One prevailing theory is that an immunocompromised person was infected with a coronavirus for an extended period of time, leading to accelerated viral evolution. Another theory speculates that omicron could have evolved in another animal species and then reinfected humans. Alternatively, omicron could have evolved gradually in a location with poor sequencing surveillance. There is still much more that needs to be understood about the factors that led to the emergence of this highly mutated variant.
Could omicron mutate to become more deadly?
The variants that have risen to prominence have done so because they contain advantageous mutations for the coronavirus. We are essentially witnessing Darwinian evolution – survival of the fittest – in real time. Variants with beneficial mutations, such as those providing escape from antibodies or shorter incubation periods, are rapidly displacing their less fit predecessors.
The most important thing to remember about virus evolution is that natural selection favors variants that spread better than other variants. The great news is that more pathogenic – or dangerous – variants are less likely to spread well. This is because individuals who feel particularly sick tend to naturally self-isolate, reducing the virus’s chance to transmit.
Also good news is that, because infection with one variant provides partial immunity to others, omicron’s rapid spread has brought on delta’s swift decline.
At this point it is expected that all new variants that spread widely – so-called variants of concern – will continue to be highly transmissible.
What about the buzz around ‘deltacron’ and ‘flurona’?
In early January 2022, researchers in Cyprus reported cases of COVID-19 infections containing sequences of both omicron and delta, dubbed “deltacron.” However, other scientists are speculating that this is nothing more than a laboratory contaminant – an omicron sample contaminated with delta. While more details are needed, as of now, there is not cause for alarm over this possible hybrid because it has not been commonly observed.
And in recent weeks the term “flurona” has surfaced, referring to an individual who is infected with both influenza virus and a coronavirus at the same time. While rare, such situations do happen, and it’s important that you reduce your risk by receiving both the influenza and COVID-19 vaccines. But it’s important to note that flurona is not a new combination of the flu and coronavirus genomes, making this term a bit of a misnomer.
Sara Sawyer is a co-founder of Darwin Biosciences. She receives funding from the National Institutes of Health and the Department of Defense.
Cody Warren receives funding from the National Institutes of Health.
Arturo Barbachano-Guerrero ne travaille pas, ne conseille pas, ne possède pas de parts, ne reçoit pas de fonds d'une organisation qui pourrait tirer profit de cet article, et n'a déclaré aucune autre affiliation que son organisme de recherche.